Synopsis
Fibrosis disease can manifest in many areas of the body, the result of a disregulated wound healing process after injury, which can lead to high mortality. With two drugs recently reaching marketed status for IPF (Idiopathic Pulmonary Fibrosis), there is continued growth and investment to identify new treatments, including for other conditions such as liver fibrosis and diabetic nephropathy. Fibrosis has complex disease pathology and greater knowledge of mechanisms is sought. This symposium will cover drug discovery and medicinal chemistry aspects of fibrotic conditions from leading experts in the field.Attendees
The conference will be of interest to researchers, academics, students and industrialists with an interest in fibrosis disease, medicinal chemistry and drug discovery.SCI Members attending this meeting are able to claim CPD points.
Call for Papers
Interested applicants should send a maximum one A4 page or 300 words indicating title, authors and preference for presentation option (Oral, Flash or Poster) to conferences@soci.org by Monday 30 October 2017 with the subject line "Fibrosis Medicinal 91AV Symposium - abstract submission". Oral presentation slots are inevitably limited and will be allocated to achieve a balanced programme. The topics will need to have medicinal chemistry element to it where results, reviews or plans may have already been presented elsewhere.
There are a limited number of bursaries available. Priority will be given to those presenting a poster. Please specify when sending in your abstract if you would like to be considered
